Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 3Endocrine 3NET 2Lymphoid 2Gastrointestinal 2CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Breast 1

Conditions

Neuroendocrine Tumors 2Neurodegenerative Diseases 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 6Magnetic Resonance Spectroscopy 3Data Collection 3telotristat ethyl 2surufatinib 2Somatostatin 2Positron-Emission Tomography 2Everolimus 2Drug Therapy 2Biopsy 2lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Positron-Emission Tomography × NET × Clear all
NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06211803 2024-01-18

JPETClinic

Jagiellonian University

Completed
10 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroendocrine Tumors, Neurodegenerative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡